Aerogen
PrivateLast Round
Series A
Extension
Mar 25, 2004
Est. Valuation
$232.8M
Total Funding Raised
$52.4M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Aerogen operates in Healthcare & Life Sciences and is based in Ireland. Its latest recorded funding round was a Series A Extension round in March 2004.
Aerogen is a drug delivery company that develops and manufactures acute care aerosol drug delivery systems for patients with respiratory disorders.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aerogen Comparables
Compare Aerogen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PARI | 81% | |
| Getinge AB | 77% | |
| Trudell Medical International | 77% |
For institutional investors. Book with your work email.
Aerogen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 25, 2004 | ||||
| IPO | Nov 13, 2000 | ||||
| Series F | Jul 7, 2000 | ||||
| Series E | Mar 13, 2000 | ||||
| Series D | Sep 17, 1998 |
For institutional investors. Book with your work email.
Aerogen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Invesco Ltd. | Series D |
| InterWest Partners | Series D |
| Perceptive Advisors | Series A Extension |
| U.S. Venture Partners | Series D |
| OrbiMed | Series A Extension |
| HealthCap | Series A Extension |
| J.P. Morgan Asset Management | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 9, 2026
Products have reached over 30 million patients in more than 80 countries.
- Jul 9, 2026
Twelve-time winner of the Zenith Award for Respiratory Care Excellence.
For institutional investors. Book with your work email.
Aerogen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aerogen's valuation, stock price, and market status.
Is Aerogen a public or private company?
Aerogen is a private company.
What is the current stock price of Aerogen?
Aerogen is a private company, so its shares have no public market price. Caplight tracks Aerogen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aerogen worth (valuation)?
Aerogen's valuation is estimated at $232.8M based on funding round data.
Can I buy Aerogen stock?
Aerogen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aerogen's last funding round?
Aerogen's most recent funding round was Series A Extension on March 25, 2004.
Who are the main investors in Aerogen?
Key investors in Aerogen include J.P. Morgan Asset Management.
Will Aerogen IPO soon?
No public IPO plans have been announced for Aerogen.
How can I track Aerogen secondary market activity?
Caplight tracks bids, offers, and trades in Aerogen's shares on secondary markets.